To explore the hot topics and development trends in the field of Alzheimer's disease (AD) through Mendelian randomization (MR) studies. Methods: Relevant English literature on MR studies of AD was retrieved from the Web of Science Core Collection database, spanning from the inception of the database to March 2024. CiteSpace 6.2.R4 was utilized for visual analysis of authors, countries, institutions, co-citation of documents, co-occurrence of keywords, and keyword clustering, and a knowledge map was constructed. Additionally, the PatSnap Global New Drug Intelligence Database was consulted to investigate the drug development status of biomarkers related to AD. Results: A total of 347 English articles were included after deduplication, with an increasing trend in annual publication volume. British scholar Ben-shlomo Yoav had the highest betweenness centrality. The top three countries in terms of publication volume were China, the United States, and the United Kingdom, while the top three countries in betweenness centrality were Poland, France, and Canada. China had the highest publication volume but only collaborated with the United States and the Netherlands. The top three institutions were University College London, Harvard University, and Fudan University. In the keyword clustering map, "#0 risk factors" was most closely related to AD biomarkers, with amyloid precursor protein (APP) and tau (TAU) emerging as more promising drug targets. Conclusion: MR studies on AD are mainly conducted in China, the UK, and the US. The primary research focus is on risk factors for AD onset, such as amyloid protein in cerebrospinal fluid. Related studies have identified APP and TAU as more important biomarkers and drug targets.